Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis [2]

Journal of Rheumatology

Volumn 31, Issue 12, 2004, Pages 2529-

  Becker, Mara ^a   Rosé, Carlos D ^a   McIlvain Simpson, Gail ^b  

^a Department of Pediatrics ^*

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; DIPHENHYDRAMINE; INFLIXIMAB; METHOTREXATE; NICOTINIC ACID; PARACETAMOL;

ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; CHILL; CLINICAL TRIAL; FEVER; FLUSHING; HUMAN; HYPERSENSITIVITY; HYPOTENSION; HYPOXIA; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LETTER; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; PSORIATIC ARTHRITIS; SINUSITIS; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; FLUSHING; FOLLOW-UP STUDIES; HUMANS; HYPEREMIA; INFUSIONS, INTRAVENOUS; MALE; NIACIN; RISK ASSESSMENT; SAMPLING STUDIES;

EID: 10044289568     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
3. Centocor, Inc. Infliximab package insert. Malvern, PA: Centocor, Inc.
4. Wilkin JK, Fortner G, Reinhardt LA, Flowers OV, Kilpatrick SJ, Streeter WC. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther 1985;38:273-7.
5. Wilkin, JK. Why is flushing limited to a mostly facial cutaneous distribution? J Am Acad Dermatol 1988;19:309-13.
6. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992;98:812-5.
7. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995;99:378-85.
8. Lobel EZ, Korelitz BI, Warman JI. Red man syndrome and infliximab [letter]. J Clin Gastroenterol 2003;36:186.
9. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.